E2F4 Transcription Factor
"E2F4 Transcription Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E2F transcription factor that represses GENETIC TRANSCRIPTION required for CELL CYCLE entry and DNA synthesis. E2F4 recruits chromatin remodeling factors indirectly to target gene PROMOTER REGIONS through RETINOBLASTOMA LIKE PROTEIN P130 and RETINOBLASTOMA LIKE PROTEIN P107.
| Descriptor ID |
D050704
|
| MeSH Number(s) |
D12.776.930.211.812
|
| Concept/Terms |
E2F4 Transcription Factor- E2F4 Transcription Factor
- Transcription Factor, E2F4
- E2F-4 Transcription Factor
- E2F 4 Transcription Factor
- Transcription Factor, E2F-4
- E2F Transcription Factor 4 Protein
- E2F-4 Protein
- E2F 4 Protein
- Transcription Factor E2F-4
- E2F-4, Transcription Factor
- Transcription Factor E2F 4
|
Below are MeSH descriptors whose meaning is more general than "E2F4 Transcription Factor".
Below are MeSH descriptors whose meaning is more specific than "E2F4 Transcription Factor".
This graph shows the total number of publications written about "E2F4 Transcription Factor" by people in this website by year, and whether "E2F4 Transcription Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "E2F4 Transcription Factor" by people in Profiles.
-
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2017 05 02; 17(1):306.
-
Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value. Mol Cancer Res. 2016 Apr; 14(4):332-43.
-
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer. Mol Cancer Res. 2015 Sep; 13(9):1316-24.
-
E2F4 regulatory program predicts patient survival prognosis in breast cancer. Breast Cancer Res. 2014 Dec 02; 16(6):486.
-
E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol. 2010 Jan; 30(2):524-36.
-
Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging. Ann N Y Acad Sci. 2007 Nov; 1119:147-64.
-
The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008 Jan 10; 27(3):366-77.
-
E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene. 2006 Jan 12; 25(2):230-9.
-
Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol. 2005 Jun; 7(6):601-11.
-
Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein. Mol Cell Biol. 2005 Feb; 25(4):1325-38.